|Day's Range||33.97 - 34.22|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.76|
|Dividend & Yield||1.28 (3.76%)|
|1y Target Est||N/A|
The FDA has approved its first commercial medicine, and because it could reshape a big indication, the company may have just gotten a lot more interesting to suitors.
Here are the names.
Rating Action: Moody's Affirms Four Classes of GCCFC 2005- GG3. Global Credit Research- 23 Jun 2017. Approximately $86.3 Million of Structured Securities Affected.